BioSpace News Archive

Eyenovia, Inc. (NASDAQ: EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-review journal Clinical Ophthalmology

Permanent Injunction Restrains Mr. Li and Mr. Cao from Purporting to Act as or Take Any Actions as Directors of Sinovac HK or its subsidiaries

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Cold Genesys, Inc. today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Cold Genesys’ lead oncolytic immunotherapy candidate CG0070 with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in a Phase 2 clinical study.

The December 13, 2018 webinar is open to hospital and health system personnel nationwide and will feature Dr. Richard E. Pratley of Florida Hospital System and Dr. Steven V. Edelman of UC San Diego Health.

Company’s New Guided Diuretic Therapy is in Development for the Optimization of Fluid Management for Patients with Heart Failure

Continuing to expand access to cancer care globally, Varian (NYSE: VAR) announced it was selected by Medical Specialist Holdings (MSH) to equip seven of its centers in South Africa with Varian linear accelerators and Eclipse™ treatment planning system.

Largest nonprofit provider of care and treatment to people with HIV/AIDS in the world is “profoundly troubled” by merger of CVS and Aetna because of its potential harmful impact on vulnerable HIV patients. Merger combines an insurer (Aetna), pharmacy benefits manager (CVS Caremark), and providers (CVS pharmacies) into a conglomerate that threatens to reduce patient choice and eliminate competition.

This study compares standard of care to SOC plus BIO-11006 in 60 patients with stage 4, NSCLC.

Eisai Inc. and METAvivor today announced the launch of Elements, a new initiative of the #ThisIsMBC campaign